AdvtAdvtList of drugs given duty waiver in Budget 2026-27No. DrugBrand nameCompanyType1RibociclibKisqaliNovartisCDK4 and CDK6 inhibitor2AbemaciclibVerzenioEli LillyCDK4 and CDK6 inhibitor3Talycabtagene autoleucelNexCAR19ImmunoActCAR-T4TremelimumabImjudoAstraZenecaCTLA-4 inhibitor5VenetoclaxVenclyxtoAbbVieBCL-2 inhibitor6CeritinibSpexibNovartisTyrosine kinase inhibitor7BrigatinibAlunbrigTakedaTyrosine kinase inhibitor8DarolutamideNubeqaBayerAndrogen receptor (AR) inhibitor9ToripalimabZytorvDr Reddy’s Lab (in-licensed)PD-1 inhibitor10SerplulimabHetroniflyIntas (in-licensed)PD-1 inhibitor11TislelizumabTevimbraGlenmark (in-licensed)PD-1 inhibitor12Inotuzumab ozogamicinInonzaPfizeranti-CD22 calicheamicin immunoconjugate13PonatinibIclusigTakedaTyrosine kinase inhibitor14IbrutinibImbruvicaAbbVieBTK inhibitor15DabrafenibTafinlarNovartisBRAF inhibitor16TrametinibMekinistNovartisMEK inhibitor17IpilimumabYervoyBristol-Myers SquibbCTLA-4 inhibitorBy ,ET PharmaJoin the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. All about ETPharma industry right on your smartphone! Download the ETPharma App and get the Realtime updates and Save your favourite articles.

Source: Economic Times February 01, 2026 13:34 UTC